Identifying effective treatments for Alzheimer's disease (AD) has proven challenging and has
instigated a shift in AD research focus toward the earliest disease-initiating cellular …

Neurodegenerative diseases, including Alzheimer's disease (AD), target specific and
functionally connected neuronal networks, raising the possibility that neurodegeneration …

The repeated failures of amyloid-targeting therapies have challenged our narrow
understanding of Alzheimer's disease (AD) pathogenesis and inspired wide-ranging …

Alzheimer's disease is the most frequent neurodegenerative disorder and the most common
cause of dementia in the elderly. Diverse lines of evidence suggest that amyloid-β (Aβ) …

The study of Alzheimer's Disease (AD) has traditionally focused on neuropathological
mechanisms that has guided therapies that attenuate neuropathological features. A new …

Our incomplete understanding of the link between Alzheimer's Disease pathology and
symptomatology is a crucial obstacle for therapeutic success. Recently, translational studies …

Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …

An essential feature of Alzheimer's disease (AD) is the accumulation of amyloid-β (Aβ)
peptides in the brain, many years to decades before the onset of overt cognitive symptoms …

The synapse has consistently been considered a vulnerable and critical target within
Alzheimer's disease, and synapse loss is, to date, one of the main biological correlates of …

Alzheimer's disease (AD) is characterized by memory loss, cognitive decline, and
devastating neurodegeneration, not only as a result of the extracellular accumulation of beta …